Necitumumab Fails to Improve Survival in Lung Cancer (NSCLC)
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, researchers have found that the addition of necitumumab to cisplatin and pemetrexed did not increase survival of previously untreated patients with stage IV non-squamous non-small cell lung cancer (NSCLC).
Necitumumab is an investigational second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody.
For the international, open-label, controlled phase III study, researchers enrolled 633 patients with previously untreated non-squamous NSCLC and randomly assigned them to receive either cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 of a 3-week cycle for up to 6 cycles alone, or with necitumumab 800mg on days 1 and 8 until disease progression or unacceptable toxicity.
Results showed a median overall survival of 11.3 months (95% CI: 9.5 - 13.4) for the necitumumab group compared with 11.5 months (10.1 - 13.1) in the chemotherapy alone group (HR = 1.01; 95% CI: 0.84 - 1.21; P = 0.96).
The necitumumab group also experienced a higher incidence of severe adverse events, including death, versus the chemotherapy alone group.
The findings suggest that necitumumab is not likely to provide benefit to patients with previously untreated stage IV non-squamous NSCLC when used in combination with cisplatin and pemetrexed.
Addition of necitumumab to cisplatin and pemetrexed did not increase survival in stage IV non-squamous NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol